Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
about
The use of metabolic profiling to identify insulin resistance in veal calvesSerum lipidomics reveals early differential effects of gastric bypass compared with banding on phospholipids and sphingolipids independent of differences in weight loss.Emerging roles for the amyloid precursor protein and derived peptides in the regulation of cellular and systemic metabolism.Coconut Oil Aggravates Pressure Overload-Induced Cardiomyopathy without Inducing Obesity, Systemic Insulin Resistance, or Cardiac SteatosisSphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.Spaceflight Activates Autophagy Programs and the Proteasome in Mouse Liver.Untargeted metabolomics identifies a plasma sphingolipid-related signature associated with lifestyle intervention in prepubertal children with obesity.The Phospholipid Linoleoylglycerophosphocholine as a Biomarker of Directly Measured Insulin Resistance.Defective STIM-mediated store operated Ca2+ entry in hepatocytes leads to metabolic dysfunction in obesity.iNKT cells prevent obesity-induced hepatic steatosis in mice in a C-C chemokine receptor 7-dependent manner.A Decade of Genetic and Metabolomic Contributions to Type 2 Diabetes Risk Prediction.Circulating Sphingolipids, Insulin, HOMA-IR and HOMA-B: the Strong Heart Family Study.Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.Immunometabolic Activation of Invariant Natural Killer T Cells.Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status.Alterations in postmenopausal plasmatic lipidomeIncreased serum concentration of ceramides in obese children with nonalcoholic fatty liver diseaseBerberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
P2860
Q36406379-5665C533-00C5-4BBF-AC2E-669FC19E6384Q38916357-510D4C77-5DBC-41B2-9379-3AF253756AB9Q39204376-C3B76805-7B87-41AC-9755-8B55068CCAF1Q41183300-30C61ED0-CB4A-49C7-9B2A-4F6C42F793BDQ45072762-A4A5125F-7BA3-4EBC-94F4-8777769A9D23Q46022686-F11F79B3-CEEC-45D4-AF7C-42DB26C9F328Q46300676-03DAFB8A-CD4B-4F74-A10E-09B932AC2CC6Q47106148-F39D207D-F121-4432-82E0-81215C0DB581Q47290995-6A8F65BC-FEEF-45BE-A32B-94A2997A1461Q48234451-93D3F651-2B90-4C41-90CB-3C607D7652DBQ48561722-AB8A495E-35E7-44BE-8238-9419EAA654B3Q51244151-27910C39-2244-4B28-ABBC-AE4639FBADD6Q51813863-040643FB-E566-4CD8-AFDD-3D0FBA042D1AQ55002337-338E88BA-691A-4931-A805-FB5F1347CA2FQ55290172-151D8AB1-78A2-4F79-8850-70108CD63329Q57161456-8CC896C4-4021-4CBC-B6BF-49E3ACD5EAB8Q58747079-FFF784DD-08E9-4D21-914A-7D3F1734BF12Q58803262-D7CB6A5D-B894-4604-9A35-2280B617BC4D
P2860
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@ast
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@en
type
label
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@ast
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@en
prefLabel
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@ast
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
@en
P2860
P356
P1476
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
@en
P2093
Peter J Meikle
Scott A Summers
P2860
P2888
P356
10.1038/NRENDO.2016.169
P577
2016-10-21T00:00:00Z